250 related articles for article (PubMed ID: 20955098)
21. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
22. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
Ewies AA; Alfhaily F
Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
[TBL] [Abstract][Full Text] [Related]
23. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
Ørbo A; Arnes M; Vereide AB; Straume B
BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
[TBL] [Abstract][Full Text] [Related]
24. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
25. Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
Arnes M; Hvingel B; Orbo A
Anticancer Res; 2014 May; 34(5):2319-24. PubMed ID: 24778038
[TBL] [Abstract][Full Text] [Related]
26. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia.
Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M
Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958
[TBL] [Abstract][Full Text] [Related]
28. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
29. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Ørbo A; Arnes M; Lyså LM; Straume B
Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
[TBL] [Abstract][Full Text] [Related]
30. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
31. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
[TBL] [Abstract][Full Text] [Related]
32. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
[TBL] [Abstract][Full Text] [Related]
33. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
[TBL] [Abstract][Full Text] [Related]
34. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower abdominal pain and back pain among women treated for menorrhagia: a five-year randomized controlled trial.
Heliövaara-Peippo S; Halmesmäki K; Hurskainen R; Teperi J; Grenman S; Kivelä A; Kujansuu E; Tuppurainen M; Vuorma S; Yliskoski M; Paavonen J
Acta Obstet Gynecol Scand; 2009; 88(12):1389-96. PubMed ID: 19878089
[TBL] [Abstract][Full Text] [Related]
35. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study.
Heikinheimo O; Vani S; Carpén O; Tapper A; Härkki P; Rutanen EM; Critchley H
Hum Reprod; 2007 Sep; 22(9):2515-22. PubMed ID: 17636280
[TBL] [Abstract][Full Text] [Related]
36. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
Haoula ZJ; Walker KF; Powell MC
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
[TBL] [Abstract][Full Text] [Related]
37. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.
Sheng J; Zhang WY; Zhang JP; Lu D
Contraception; 2009 Mar; 79(3):189-93. PubMed ID: 19185671
[TBL] [Abstract][Full Text] [Related]
38. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women.
Hampton NR; Rees MC; Lowe DG; Rauramo I; Barlow D; Guillebaud J
Hum Reprod; 2005 Sep; 20(9):2653-60. PubMed ID: 15905289
[TBL] [Abstract][Full Text] [Related]
39. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Kresowik J; Ryan GL; Van Voorhis BJ
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
[TBL] [Abstract][Full Text] [Related]
40. [Effects of levonorgestrel intrauterine system on endometrial tissue after endometrial polyps resection by hysteroscopy].
Cai HL; Ding XC; Qian RR; Yu RF; Sun LM; Li Q
Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(3):200-2. PubMed ID: 22490745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]